双特异性抗体免疫疗法在B细胞非霍奇金淋巴瘤中的研究进展

Research progress of bispecific antibodies immunotherapy in B-cell non-Hodgkin lymphoma

双特异性抗体(BsAb)在血液系统恶性肿瘤中的应用已经取得显著进展。BsAb能够通过主要组织相容性复合体非限制性介导细胞毒性T细胞靶向杀伤肿瘤细胞。在B细胞非霍奇金淋巴瘤(B-NHL)患者中,靶向CD20和CD3的BsAb的早期临床试验已显示出良好的有效性和安全性。该研究主要就靶向不同靶点的BsAb的结构特点、在B-NHL中应用的疗效反应、不良反应,以及BsAb耐药机制的相关研究进展进行综述。

Significant progress has been made in the application of bispecific antibodies(BsAb)in hematological malignancies.BsAb can target and kill tumor cells through major histocompatibility complex non-limiting cytotoxic T cells.In patients with B-cell non-Hodgkin′s lymphoma(B-NHL),early clinical trials of BsAb targeting CD20 and CD3 have shown good efficacy and safety.This article mainly reviews the structural characteristics of BsAb targeting different targets,the therapeutic effects and adverse reactions of its application in B-NHL,and the related research progress of BsAb drug resistance mechanism.